Format

Send to:

Choose Destination
See comment in PubMed Commons below
Annu Rev Pharmacol Toxicol. 2010;50:423-37. doi: 10.1146/annurev.pharmtox.010909.105805.

Economic opportunities and challenges for pharmacogenomics.

Author information

  • 1UNC Institute for Pharmacogenomics and Individualized Therapy, Department of Health Policy and Management, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA. pat_deverka@unc.edu

Abstract

Economic evaluation provides health care decision makers with a powerful tool for resource allocation decisions because it offers a framework for comparing the costs and benefits of competing interventions or options. This paper reviews how economic analyses have been applied to the field of pharmacogenomics, both by the pharmaceutical industry to inform investment decisions and by payers to make coverage decisions. There is much anticipation that pharmacogenomic testing is likely to be cost-effective because it uses genomic information to improve drug effectiveness and reduce toxicity both in the drug development process and at the bedside. However, the demonstration of economic benefits first requires that pharmacogenomic testing show evidence of clinical effectiveness. This will only be achieved by greater participation of pharmacogenomics experts in comparative effectiveness research and additional emphasis on including costs in the determination of the relative value of pharmacogenomic testing to the health care system.

PMID:
20055709
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Write to the Help Desk